

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

ETAS ID: TM323602

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT		
<b>NATURE OF CONVEYANCE:</b>	SECURITY INTEREST		
<b>CONVEYING PARTY DATA</b>			
<b>Name</b>	<b>Formerly</b>	<b>Execution Date</b>	<b>Entity Type</b>
Interpace Diagnostics Corporation		11/03/2014	CORPORATION: DELAWARE
<b>RECEIVING PARTY DATA</b>			
<b>Name:</b>	SWK Funding LLC, As Agent		
<b>Street Address:</b>	15770 North Dallas Parkway		
<b>Internal Address:</b>	Suite 1290		
<b>City:</b>	Dallas		
<b>State/Country:</b>	TEXAS		
<b>Postal Code:</b>	75248		
<b>Entity Type:</b>	LIMITED LIABILITY COMPANY: TEXAS		
<b>PROPERTY NUMBERS Total: 1</b>			
<b>Property Type</b>	<b>Number</b>	<b>Word Mark</b>	
<b>Registration Number:</b>	3208314	PATHFINDERTG	
<b>CORRESPONDENCE DATA</b>			
<b>Fax Number:</b>	2149649501		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
<b>Phone:</b>	2149649459		
<b>Email:</b>	ryan.magee@hklaw.com		
<b>Correspondent Name:</b>	Ryan Magee		
<b>Address Line 1:</b>	Holland & Knight LLP		
<b>Address Line 2:</b>	200 Crescent Court, Suite 1600		
<b>Address Line 4:</b>	Dallas, TEXAS 75201		
<b>ATTORNEY DOCKET NUMBER:</b>	136144-18/MADREWS		
<b>NAME OF SUBMITTER:</b>	Ryan Magee		
<b>SIGNATURE:</b>	/Ryan Magee/		
<b>DATE SIGNED:</b>	11/18/2014		
<b>Total Attachments: 16</b>			
source=Interpace IP Security Agreement for recording#page1.tif			
source=Interpace IP Security Agreement for recording#page2.tif			
source=Interpace IP Security Agreement for recording#page3.tif			

OP \$40.00 3208314

TRADEMARK

source=Interpace IP Security Agreement for recording#page4.tif  
source=Interpace IP Security Agreement for recording#page5.tif  
source=Interpace IP Security Agreement for recording#page6.tif  
source=Interpace IP Security Agreement for recording#page7.tif  
source=Interpace IP Security Agreement for recording#page8.tif  
source=Interpace IP Security Agreement for recording#page9.tif  
source=Interpace IP Security Agreement for recording#page10.tif  
source=Interpace IP Security Agreement for recording#page11.tif  
source=Interpace IP Security Agreement for recording#page12.tif  
source=Interpace IP Security Agreement for recording#page13.tif  
source=Interpace IP Security Agreement for recording#page14.tif  
source=Interpace IP Security Agreement for recording#page15.tif  
source=Interpace IP Security Agreement for recording#page16.tif

## INTELLECTUAL PROPERTY SECURITY AGREEMENT

This INTELLECTUAL PROPERTY SECURITY AGREEMENT, dated as of November 3, 2014 (as may be amended, restated, supplemented, or otherwise modified from time to time, this “**Agreement**”), made by Interpace Diagnostics Corporation, a Delaware limited liability company (the “**Grantor**”), in favor of SWK FUNDING LLC, a Delaware limited liability company, as collateral agent (in such capacity, “**Agent**”) for the Lenders (as defined below) party to the Credit Agreement (as defined below).

### W I T N E S S E T H:

WHEREAS, pursuant to that certain Credit Agreement, dated as of November 3, 2014 (as amended, restated, supplemented or otherwise modified from time to time, the “**Credit Agreement**”), by and among PDI, INC., a Delaware corporation (“**Borrower**”), Agent and the financial institutions party thereto from time to time as lenders (each a “**Lender**” and collectively, the “**Lenders**”), Agent and Lenders have agreed to make certain financial accommodations available to Borrower, and Borrower has granted a security interest to Agent, for the benefit of Lenders, in, among other things, all right, title and interest of Borrower in, to and under all of Borrower’s Intellectual Property (as defined below), whether now existing or hereafter arising or acquired as security for the Obligations;

WHEREAS, the Borrower is affiliated with the Grantor. The Borrower and the Grantor are engaged in interrelated businesses, and the Grantor will derive substantial direct and indirect benefit from extensions of credit under the Credit Agreement; and

WHEREAS, The Grantor is the owner of the entire right, title and interest in, to and under the Intellectual Property listed on Schedule I hereto as applicable.

NOW, THEREFORE, in consideration of the premises and to induce Agent and Lenders to enter into the Credit Agreement, the Grantor hereby agrees with Agent as follows:

#### 1. Defined Terms.

(a) Definitions. Unless otherwise defined herein or the context otherwise requires, terms used in this Agreement, including its preamble and recitals, have the meanings provided in the Credit Agreement.

(b) Definitions of Certain Terms Used Herein. As used herein, the following terms shall have the following meanings:

“**Copyrights**” shall mean all of the Grantor’s (or if referring to another Person, such other Person’s) now existing or hereafter acquired right, title, and interest in and to: (i) copyrights, rights and interests in copyrights, works protectable by copyright, all applications, registrations and recordings relating to the foregoing as may at any time be filed in the United States Copyright Office or in any similar office or agency of the United States, any State thereof, any political subdivision thereof or in any other country, and all research and development relating to the foregoing; and (ii) all renewals of any of the foregoing.

“**Copyright Licenses**” shall mean all written agreements naming the Grantor as licensor or licensee, granting any right under any Copyright, including the grant of rights to manufacture, distribute, exploit and sell materials derived from any Copyright (other than agreements relating to widely-available software subject to “shrink-wrap” or “click-through” software licenses).

“**Credit Agreement**” shall have the meaning assigned to such term in the recitals of this Agreement.

“**Intellectual Property**” shall mean all present and future: trade secrets, know-how and other proprietary information; Trademarks, internet domain names, service marks, trade dress, trade names, business names, designs, logos, slogans (and all translations, adaptations, derivations and combinations of the foregoing) indicia and other source and/or business identifiers, and the goodwill of the business relating thereto and all registrations or applications for registrations which have heretofore been or may hereafter be issued thereon throughout the world; Copyrights (including Copyrights for computer programs, but excluding commercially available off-the-shelf software and any Intellectual Property rights relating thereto) and all tangible and intangible property embodying the Copyrights, unpatented inventions (whether or not patentable); Patents; industrial design applications and registered industrial designs; license agreements related to any of the foregoing and income therefrom, books, records, writings, computer tapes or disks, flow diagrams, specification sheets, computer software, source codes, object codes, executable code, data, databases and other physical manifestations, embodiments or incorporations of any of the foregoing; the right to sue for all past, present and future infringements of any of the foregoing; all other intellectual property; and all common law and other rights throughout the world in and to all of the foregoing.

“**IP Collateral**” shall have the meaning assigned to such term in Section 2 hereof.

“**Licenses**” shall mean, collectively, the Trademark Licenses, the Patent Licenses, and the Copyright Licenses.

“**Patents**” shall mean all of the Grantor’s (or if referring to another Person, such other Person’s) now existing or hereafter acquired right, title and interest in and to: (i) all patents, patent applications, inventions, invention disclosures and improvements, and all applications, registrations and recordings relating to the foregoing as may at any time be filed in the United States Patent and Trademark Office or in any similar office or agency of the United States, any state thereof, any political subdivision thereof or in any other country, and all research and development relating to the foregoing; and (ii) the reissues, divisions, continuations, renewals, extensions and continuations-in-part of any of the foregoing.

“**Patent Licenses**” shall mean all agreements, whether written or oral, providing for the grant by or to the Grantor of any right to manufacture, develop, market, use or sell any products derived, in whole or in part, from any invention covered by a Patent or any similar agreement related to any other use of any invention covered by a Patent.

“**Trademarks**” shall mean all of the Grantor’s (or if referring to another Person, such other Person’s) now existing or hereafter acquired right, title, and interest in and to: (i) all of the Grantor’s (or if referring to another Person, such other Person’s) trademarks, trade names, corporate names, company names, business names, fictitious business names, trade styles, service marks, logos, other business identifiers, all applications, registrations and recordings relating to the foregoing as may at any time be filed in the United States Patent and Trademark Office or in any similar office or agency of the United States, any State thereof, any political subdivision thereof or in any other country, and all research and development relating to the foregoing; (ii) all renewals thereof; and (iii) all designs and general intangibles of a like nature.

“**Trademark Licenses**” shall mean, collectively, each agreement, whether written or oral, providing for the grant by or to the Grantor of any right to use any Trademark.

(c) **Other Definitional Provisions.**

(i) The words “hereof,” “herein” and “hereunder” and words of similar import when used in this Agreement shall refer to this Agreement as a whole and not to any particular provision of this Agreement, and section and paragraph references are to this Agreement unless otherwise specified.

(ii) The meanings given to terms defined herein shall be equally applicable to both the singular and plural forms of such terms.

2. **Grant of Security Interest.** To secure the payment and performance of the Obligations, the Grantor hereby confirms and acknowledges that it has granted (and, to the extent not previously granted under the Guarantee and Collateral Agreement, does hereby grant) to Agent, for the benefit of Lenders, a lien and security interest in the Grantor’s entire right, title and interest in its Intellectual Property and all proprietary rights relating to or arising from such Intellectual Property, in each case whether now owned or hereafter acquired by the Grantor, and including, without limitation, the Grantor’s right, title and interest in and to the Intellectual Property and proprietary rights identified on Schedule I attached hereto and made a part hereof, and the right to sue for past, present and future infringements and dilutions, and all rights corresponding thereto throughout the world, and the entire goodwill of the Grantor’s business connected with and symbolized by such Intellectual Property and all income, fees, royalties, proceeds and other payments at any time due or payable with respect to any of the foregoing (referred to collectively as the “**IP Collateral**”); provided, that the IP Collateral shall not include the Excluded Property (as defined in the Guarantee and Collateral Agreement).

3. **Protection of Intellectual Property by Grantor.** The Grantor shall, at its sole cost, expense and risk, in connection with the operation of its business, comply with the requirements set forth in Section 5.7 of the Guarantee and Collateral Agreement in respect to the Intellectual Property.

4. **Representations and Warranties.** The Grantor represents and warrants that:

(a) Schedule I is a true, correct and complete list of all registered or applied-for Intellectual Property in which the Grantor purports to have an ownership or license interest.

(b) The Grantor has the legal right and authority to enter into this Agreement and perform its terms.

(c) If the Grantor amends its name, the Grantor shall provide copies of such amendment documentation to Agent and shall re-register the Grantor’s Intellectual Property with the appropriate Governmental Authority and shall execute and deliver such agreements or documentation as Agent shall request to maintain a perfected first priority security interest in such Intellectual Property subject to Permitted Liens.

5. **No Violation of Credit Agreement.** The representations, warranties or covenants contained herein are supplemental to those representations, warranties and covenants contained in the other Loan Documents, and shall not be deemed to modify any such representation, warranty or covenant contained in any other Loan Document.

**6. Agreement Applies to Future Intellectual Property.**

(a) The provisions of this Agreement shall automatically apply to any such additional property or rights described in Section 2 above, all of which shall be deemed to be and treated as “IP Collateral” within the meaning of this Agreement.

(b) Upon the request of Agent, the Grantor shall execute and deliver, and have recorded, any and all agreements, instruments, documents and papers as Agent may reasonably request to evidence Agent’s security interest in any IP Collateral and the goodwill of the Grantor relating thereto or represented thereby (including, without limitation, filings with the United States Patent and Trademark Office or any similar office), and the Grantor hereby constitutes Agent as its attorney-in-fact to execute and file all such writings for the foregoing purposes, all acts of such attorney being hereby ratified and confirmed; provided, however, that Agent’s taking of such action shall not be a condition to the creation or perfection of the security interest created hereby.

**7. Grantor’s Rights to Enforce Intellectual Property.** Prior to Agent’s giving of notice to the Grantor following the occurrence and during the continuance of an Event of Default, the Grantor shall have the exclusive right to sue for past, present and future infringement of the IP Collateral, including the right to seek injunctions and/or money damages, in an effort by the Grantor to protect the IP Collateral against encroachment by third parties, provided, however, that:

(a) Any money damages awarded or received by the Grantor on account of such suit (or the threat of such suit) shall constitute IP Collateral.

(b) Any damages recovered in any action pursuant to this Section, net of costs and attorneys’ fees reasonably incurred, shall be applied in accordance with the Credit Agreement and the Guarantee and Collateral Agreement.

(c) Following the occurrence and during the continuance of any Event of Default, Agent, by notice to the Grantor may terminate or limit the Grantor’s rights under this Section 7.

**8. Agent’s Actions to Protect Intellectual Property.** Pursuant to and in accordance with the Credit Agreement, Agent, acting in its own name or in that of the Grantor, may (but shall not be required to) act in the Grantor’s place and stead and/or in Agent’s own right with respect to the rights and obligations of the Grantor under Section 3, Section 6 and Section 7 hereof.

**9. Rights Upon Default.** Upon the occurrence and during the continuance of any Event of Default, Agent may exercise all rights and remedies as provided for in the Credit Agreement.

**10. Agent as Attorney In Fact.**

(a) The Grantor hereby irrevocably constitutes and designates Agent as its attorney-in-fact to:

(i) Following the occurrence and during the continuance of an Event of Default, supplement and amend from time to time Schedule I of this Agreement to include any new or additional Intellectual Property of the Grantor.

- (ii) Exercise any of the rights and powers referenced herein in accordance with this Agreement.
- (b) The grant of a power of attorney, being coupled with an interest, shall be irrevocable until the Obligations are paid in full.
- (c) Agent shall not be obligated to do any of the acts or to exercise any of the powers authorized by Section 8, Section 9 or Section 10 of this Agreement, but if Agent elects to do any such act or to exercise any of such powers, it shall not be accountable for more than it actually receives as a result of such exercise of power, and shall not be responsible to the Grantor for any act or omission to act, except to the extent Agent acted with gross negligence or willful misconduct as determined by a court of competent jurisdiction.

11. **Agent's Rights.** Upon an Event of Default and during the continuance thereof, any use by Agent of the IP Collateral, as authorized hereunder in connection with the exercise of Agent's rights and remedies under this Agreement and under the Credit Agreement shall be coextensive with the Grantor's rights thereunder and with respect thereto and without any liability for royalties or other related charges.

12. **No Limitation; Loan Documents.** This Agreement has been executed and delivered by the Grantor for the purpose of recording the security interest granted to Agent with respect to the IP Collateral with the United States Patent and Trademark Office, the United States Copyright Office, as well as with any similar office or department of any other foreign or domestic Governmental Authority. The security interest granted hereby has been granted as a supplement to, and not in limitation of, the security interest granted to Agent, for the benefit of Lender, under the Guarantee and Collateral Agreement and the other Loan Documents. The other Loan Documents (and all rights and remedies of the Grantor, Agent, and Lenders thereunder) shall remain in full force and effect in accordance with their terms.

13. **Termination; Release of Trademark Collateral.** This Agreement and all obligations of the Grantor and Agent hereunder shall terminate on the date upon which the Obligations are performed in full and paid in full. Upon termination of this Agreement, Agent shall, at the expense of the Grantor, take such actions required by the Credit Agreement or the Guarantee and Collateral Agreement or as otherwise reasonably requested by the Grantor to release its security interest in the IP Collateral.

14. **Binding Effect; Benefits.** This Agreement shall be binding upon the Grantor and its successors and assigns, and shall inure to the benefit of Agent, Lenders and their respective successors and assigns.

15. **GOVERNING LAW.**

THIS AGREEMENT AND THE RIGHTS AND OBLIGATIONS OF THE PARTIES HEREUNDER SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE INTERNAL LAWS OF THE STATE OF NEW YORK WITHOUT GIVING EFFECT TO ITS CHOICE OF LAW PROVISIONS THAT WOULD REQUIRE THE APPLICATION OF THE LAWS OF ANY OTHER JURISDICTION.

16. **Copy of Agreement.** The Grantor acknowledges receipt of a signed copy of this Agreement.

*[Remainder of page intentionally blank; signature page follows.]*

**IN WITNESS WHEREOF**, the parties have caused this Intellectual Property Security Agreement to be executed by its duly authorized representatives as of the date first above written.

**GRANTOR:**

**INTERPACE DIAGNOSTICS  
CORPORATION,**  
a Delaware limited liability company

By: \_\_\_\_\_

Name: Nancy S. Lurker

Title: President

*Nancy Lurker*

[Signature Page to Intellectual Property Security Agreement]

#33722252

**TRADEMARK**  
**REEL: 005403 FRAME: 0800**



AGENT:

SWK FUNDING LLC,  
a Delaware limited liability company

By:   
Name: Winston Black  
Title: Managing Director

[Signature Page to Intellectual Property Security Agreement]

## INTELLECTUAL PROPERTY

### Licenses

*none*

### Copyrights

*none*

### Patents

<u>Pat. No/ App. No.</u>	<u>Country</u>	<u>Status</u>	<u>Title</u>	<u>Filing Date</u>	<u>Issue Date</u>	<u>Assignee</u>
2584989	CA	Abandoned	MOLECULAR ANALYSIS OF CELLULAR FLUID AND LIQUID CYTOLOGY SPECIMENS FOR CLINICAL DIAGNOSIS, CHARACTERIZATION, AND INTEGRATION WITH MICROSCOPIC PATHOLOGY EVALUATION	10/24/2005		RedPath Integrated Pathology, Inc.
2585025	CA	Abandoned	DYNAMIC GENOMIC DELETION EXPANSION AND FORMULATION OF MOLECULAR MARKER PANELS FOR INTEGRATED MOLECULAR PATHOLOGY DIAGNOSIS AND CHARACTERIZATION OF TISSUE, CELLULAR FLUID, AND PURE FLUID SPECIMENS	10/24/2005		RedPath Integrated Pathology, Inc.
2584723	CA	Abandoned	ENHANCED AMPLIFIABILITY OF MINUTE FIXATIVE-TREATED TISSUE SAMPLES, MINUTE STAINED CYTOLOGY SAMPLES, AND OTHER MINUTE SOURCES OF DNA	10/24/2005		RedPath Integrated Pathology, Inc.

<u>Pat. No/ App. No.</u>	<u>Country</u>	<u>Status</u>	<u>Title</u>	<u>Filing Date</u>	<u>Issue Date</u>	<u>Assignee</u>
05818189.2	EP	Abandoned	MOLECULAR ANALYSIS OF CELLULAR FLUID AND LIQUID CYTOLOGY SPECIMENS FOR CLINICAL DIAGNOSIS, CHARACTERIZATION, AND INTEGRATION WITH MICROSCOPIC PATHOLOGY EVALUATION	10/24/2005		RedPath Integrated Pathology, Inc.
05818314.6	EP	Abandoned	DYNAMIC GENOMIC DELETION EXPANSION AND FORMULATION OF MOLECULAR MARKER PANELS FOR INTEGRATED MOLECULAR PATHOLOGY DIAGNOSIS AND CHARACTERIZATION OF TISSUE, CELLULAR FLUID, AND PURE FLUID SPECIMENS	10/24/2005		RedPath Integrated Pathology, Inc.
05817148.9	EP	Abandoned	ENHANCED AMPLIFIABILITY OF MINUTE FIXATIVE-TREATED TISSUE SAMPLES, MINUTE STAINED CYTOLOGY SAMPLES, AND OTHER MINUTE SOURCES OF DNA	10/24/2005		RedPath Integrated Pathology, Inc.
60/620926	US	Expired	TOPOGRAPHIC GENOTYPING FOR DEFINING THE DIAGNOSIS, MALIGNANT POTENTIAL, AND BIOLOGICAL BEHAVIOR OF PANCREATIC CYSTS AND RELATED CONDITIONS	10/22/2004		RedPath Integrated Pathology, Inc.

<u>Pat. No/ App. No.</u>	<u>Country</u>	<u>Status</u>	<u>Title</u>	<u>Filing Date</u>	<u>Issue Date</u>	<u>Assignee</u>
11/255978	US	Abandoned	TOPOGRAPHIC GENOTYPING FOR DETERMINING THE DIAGNOSIS, MALIGNANT POTENTIAL, AND BIOLOGIC BEHAVIOR OF PANCREATIC CYSTS AND RELATED CONDITIONS	10/24/2005		RedPath Integrated Pathology, Inc.
60/631240	US	Expired	TOPOGRAPHIC GENOTYPING FOR DETERMINING THE DIAGNOSIS, MALIGNANT POTENTIAL, AND BIOLOGIC BEHAVIOR OF PANCREATIC CYSTS AND RELATED CONDITIONS	11/29/2004		RedPath Integrated Pathology, Inc.
11/256150	US	Abandoned	MOLECULAR ANALYSIS OF CELLULAR FLUID AND LIQUID CYTOLOGY SPECIMENS FOR CLINICAL DIAGNOSIS, CHARACTERIZATION, AND INTEGRATION WITH MICROSCOPIC PATHOLOGY EVALUATION	10/24/2005		RedPath Integrated Pathology, Inc.
60/644568	US	Expired	TOPOGRAPHIC GENOTYPING FOR DETERMINING THE DIAGNOSIS, MALIGNANT POTENTIAL, AND BIOLOGIC BEHAVIOR OF PANCREATIC CYSTS AND RELATED CONDITIONS	01/19/2005		RedPath Integrated Pathology, Inc.

<u>Pat. No/ App. No.</u>	<u>Country</u>	<u>Status</u>	<u>Title</u>	<u>Filing Date</u>	<u>Issue Date</u>	<u>Assignee</u>
11/256152	US	Abandoned	DYNAMIC GENOMIC DELETION EXPANSION AND FORMULATION OF MOLECULAR MARKER PANELS FOR INTEGRATED MOLECULAR PATHOLOGY DIAGNOSIS AND CHARACTERIZATION OF TISSUE, CELLULAR FLUID, AND PURE FLUID SPECIMENS	10/24/2005		RedPath Integrated Pathology, Inc.
60/679968	US	Expired	MOLECULAR ANALYSIS OF CELLULAR FLUIDS SPECIMENS FOR CLINICAL DIAGNOSIS, CHARACTERIZATION, AND INTEGRATION WITH MICROSCOPIC PATHOLOGY EVALUATION	05/12/2005		RedPath Integrated Pathology, Inc.
11/255980	US	Abandoned	ENHANCED AMPLIFIABILITY OF MINUTE FIXATIVE-TREATED TISSUE SAMPLES, MINUTE STAINED CYTOLOGY SAMPLES, AND OTHER MINUTE SOURCES OF DNA	10/24/2005		RedPath Integrated Pathology, Inc.
60/679969	US	Expired	DYNAMIC GENOMIC DELETION EXPANSION: A PREDICTOR OF CANCER BIOLOGICAL AGGRESSIVENESS	05/12/2005		RedPath Integrated Pathology, Inc.
14/305,727	US	Pending	TOPOGRAPHIC GENOTYPING FOR DETERMINING THE DIAGNOSIS, MALIGNANT POTENTIAL, AND BIOLOGIC BEHAVIOR OF PANCREATIC CYSTS AND RELATED CONDITIONS	6/16/2014		RedPath Integrated Pathology, Inc.

<u>Pat. No/ App. No.</u>	<u>Country</u>	<u>Status</u>	<u>Title</u>	<u>Filing Date</u>	<u>Issue Date</u>	<u>Assignee</u>
US2005/038315	PCT	Expired	MOLECULAR ANALYSIS OF CELLULAR FLUID AND LIQUID CYTOLOGY SPECIMENS FOR CLINICAL DIAGNOSIS, CHARACTERIZATION, AND INTEGRATION WITH MICROSCOPIC PATHOLOGY EVALUATION	10/24/2005		RedPath Integrated Pathology, Inc.
US2005/038313	PCT	Expired	DYNAMIC GENOMIC DELETION EXPANSION AND FORMULATION OF MOLECULAR MARKER PANELS FOR INTEGRATED MOLECULAR PATHOLOGY DIAGNOSIS AND CHARACTERIZATION OF TISSUE, CELLULAR FLUID, AND PURE FLUID SPECIMENS	10/24/2005		RedPath Integrated Pathology, Inc.
US2005/038311	PCT	Expired	ENHANCED AMPLIFIABILITY OF MINUTE FIXATIVE-TREATED TISSUE SAMPLES, MINUTE STAINED CYTOLOGY SAMPLES, AND OTHER MINUTE SOURCES OF DNA	10/24/2005		RedPath Integrated Pathology, Inc.
US2005/038312	PCT	Expired	TOPOGRAPHIC GENOTYPING FOR DETERMINING THE DIAGNOSIS, MALIGNANT POTENTIAL, AND BIOLOGIC BEHAVIOR OF PANCREATIC CYSTS AND RELATED CONDITIONS	10/24/2005		RedPath Integrated Pathology, Inc.
2198774	CA	Abandoned	TOPOGRAPHIC GENOTYPING	09/22/1995		RedPath Integrated Pathology, Inc.

<u>Pat. No/ App. No.</u>	<u>Country</u>	<u>Status</u>	<u>Title</u>	<u>Filing Date</u>	<u>Issue Date</u>	<u>Assignee</u>
95935153.7	EP	Abandoned	TOPOGRAPHIC GENOTYPING	09/22/1995		RedPath Integrated Pathology, Inc.
8-511138	JP	Abandoned	TOPOGRAPHIC GENOTYPING	09/22/1995		RedPath Integrated Pathology, Inc.
6,340,563 (08/667493)	US	Granted	TOPOGRAPHIC GENOTYPING	06/24/1996	01/22/2002	RedPath Integrated Pathology, Inc.
7,014,999 (10/008278)	US	Granted	TOPOGRAPHIC GENOTYPING	11/05/2001	03/21/2006	RedPath Integrated Pathology, Inc.
11/289624	US	Abandoned	TOPOGRAPHIC GENOTYPING	11/30/2005		RedPath Integrated Pathology, Inc.
08/311553	US	Abandoned	TOPOGRAPHIC GENOTYPING	09/23/1994		RedPath Integrated Pathology, Inc.
US95/12372	PCT	Expired	TOPOGRAPHIC GENOTYPING	09/22/1995		RedPath Integrated Pathology, Inc.
61/240919	US	Abandoned	GENERATION OF A COMPREHENSIVE PATHOLOGY REPORT BASED ON MOLECULAR AND GENETIC ANALYSIS	09/09/2009		RedPath Integrated Pathology, Inc.
61/294355	US	Abandoned	METHODS OF COMPARATIVE MUTATIONAL PROFILING	01/12/2010		RedPath Integrated Pathology, Inc.
61/429908	US	Expired	METHODS OF COMPARATIVE MUTATIONAL PROFILING	01/05/2011		RedPath Integrated Pathology, Inc.
61/292561	US	Abandoned	METHODS OF IDENTIFYING BLOOD AND BLOOD-DERIVED DNA CONTENT IN CYST	01/06/2010		RedPath Integrated Pathology, Inc.
61/429900	US	Expired	METHODS OF IDENTIFYING BLOOD AND BLOOD-DERIVED DNA CONTENT IN CYST	01/05/2011		RedPath Integrated Pathology, Inc.

<u>Pat. No/ App. No.</u>	<u>Country</u>	<u>Status</u>	<u>Title</u>	<u>Filing Date</u>	<u>Issue Date</u>	<u>Assignee</u>
61/297136	US	Abandoned	METHOD OF GENERATING A PATHOLOGY REPORT FOR COMPARATIVE MUTATIONAL PROFILING	01/21/2010		RedPath Integrated Pathology, Inc.
61/425109	US	Expired	MOLECULAR DISCRIMINATION BETWEEN SPORADIC VERSUS TOXIN-ASSOCIATED CANCER FORMATION	12/20/2010		RedPath Integrated Pathology, Inc.
13/331966	US	Abandoned	METHODS OF DIFFERENTIATING BETWEEN NON-GENOTOXIN AND GENOTOXIN-ASSOCIATED TUMORS	12/20/2011		RedPath Integrated Pathology, Inc.
61/443014	US	Expired	METHODS OF DIFFERENTIATING BETWEEN NON-GENOTOXIN VERSUS GENOTOXIN-ASSOCIATED TUMORS	02/15/2011		RedPath Integrated Pathology, Inc.
61/549684	US	Expired	METHODS OF GENOTYPING DNA FROM RESIDUAL SUPERNATANT FLUID FROM BIOLOGICAL SPECIMENS	10/20/2011		RedPath Integrated Pathology, Inc.
61/565879	US	Expired	METHODS OF IDENTIFYING DYSPLASIA IN A SUBJECT	12/01/2011		RedPath Integrated Pathology, Inc.
13/692727	US	Pending	METHODS FOR TREATING BARRETT'S METAPLASIA AND ESOPHAGEAL ADENOCARCINOMA	12/03/2012		RedPath Integrated Pathology, Inc.
13/954247	US	Pending	METHODS FOR TREATING BARRETT'S METAPLASIA AND ESOPHAGEAL ADENOCARCINOMA	07/30/2013		RedPath Integrated Pathology, Inc.



<u>Pat. No/ App. No.</u>	<u>Country</u>	<u>Status</u>	<u>Title</u>	<u>Filing Date</u>	<u>Issue Date</u>	<u>Assignee</u>
US14/46702	PCT	Pending	METHODS FOR TREATING BARRETT'S METAPLASIA AND ESOPHAGEAL ADENOCARCINOMA	07/15/2014		RedPath Integrated Pathology, Inc.
61/612061	US	Expired	METHODS OF GENOTYPING DNA FROM RESIDUAL RADIOCONTRAST AGENT	03/16/2012		RedPath Integrated Pathology, Inc.
61/640527	US	Expired	METHODS FOR DIAGNOSING LOW AND HIGH GRADE DYSPLASIA IN BARRETT'S ESOPHAGUS	04/30/2012		RedPath Integrated Pathology, Inc.
61/661256	US	Expired	METHODS FOR DIAGNOSING LOW AND HIGH GRADE DYSPLASIA IN BARRETT'S ESOPHAGUS	06/18/2012		RedPath Integrated Pathology, Inc.
61/731725	US	Expired	METHODS FOR MEASURING CARCINOEMBRYONIC ANTIGEN	11/30/2012		RedPath Integrated Pathology, Inc.
14/092,036	US	Pending	METHODS FOR MEASURING CARCINOEMBRYONIC ANTIGEN	11/27/2013		RedPath Integrated Pathology, Inc.
61/824623	US	Expired	METHODS FOR MEASURING CARCINOEMBRYONIC ANTIGEN	05/17/2013		RedPath Integrated Pathology, Inc.
61/840963	US	Expired	METHODS FOR MEASURING CARCINOEMBRYONIC ANTIGEN	06/28/2013		RedPath Integrated Pathology, Inc.

*Trademarks:*

<u>Country</u>	<u>Mark</u>	<u>Reg./App. No.</u>	<u>Filing Date</u>	<u>Reg. Date</u>	<u>Goods</u>	<u>Registrant</u>	<u>Status</u>
US	PATHFINDERTG	3208314 (78/848127)	3/28/06	2/13/07	IC042 - Medical laboratory services, namely, testing and analysis of tissue or fluids for diagnostic and forensic purposes	RedPath Integrated Pathology, Inc.	Registered